Microbix Biosystems Inc T.MBX

Alternate Symbol(s): MBXBF

Healthcare Biotechnology

Microbix Biosystems Inc. develops and commercializes biological and technological solutions for human health and wellbeing. It enables the commercialization of diagnostic assays by making a range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its segments include development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and, and development and commercialization of novel and proprietary products or technologies, such as Kinlytic. Its Kinlytic urokinase is a biologic thrombolytic drug used to treat blood clots.

TSX:MBX - Post by User

Microbix Biosystems Inc > New Press Release - Microbix Reports Record Product Sales for Q4 and Fiscal 2024

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Dec 19, 2024 8:35am

94 Views

Post# 36369886

RE:New Press Release - Microbix Reports Record Product Sales for Q4 and Fiscal 2024

Qtr ending	Revenue	Net income	cfo	Adj ebitda	Gross margin	Cogs	ebitda margin
Sep 24	6,293,897	440,324	1,096,684	1,470,637	54.8%	2,843,551	23.4%
Jun 24	5,059,465	246,746	799,430	773,861	54.3%	2,311,411	15.3%
Mar 24	5,632,901	377,730	1,083,389	1,054,114	52.7%	2,661,932	18.7%
Dec 23	8,407,884	2,455,379	3,142,178	3,150,544	74.0%	2,185,553	37.5%
Sep 23	4,263,655	1,997,271	(498,488)	(589,323)	33.4%	2,839,035	(13.8%)
Jun 23	5,530,726	(769,108)	(167,192)	(118,287)	42.4%	3,187,267	(2.1%)
Mar 23	4,218,323	31,616	599,009	649,581	59.9%	1,691,043	15.4%
Dec 22	2,502,072	(1,299,262)	(808,050)	(785,916)	47.4%	1,316,097	(31.4%)